scholarly journals Marked Reduction in 28-Day Mortality Among Elderly Patients with Severe Community-Acquired Pneumonia: Post Hoc Analysis of a Large Randomized Controlled Trial [Corrigendum]

2020 ◽  
Vol Volume 15 ◽  
pp. 2231-2232
Author(s):  
Yan Liu ◽  
Chi Zhang ◽  
Chengyu Li ◽  
Chunxue Bai ◽  
Hongcai Shang
Keyword(s):  
Randomized Controlled Trial ◽  
Elderly Patients ◽  
Marked Reduction ◽  
Controlled Trial ◽  
Community Acquired Pneumonia ◽  
Post Hoc Analysis ◽  
Randomized Controlled ◽  
Severe Community Acquired Pneumonia ◽  
Post Hoc

scholarly journals Effect of Liraglutide on Cardiovascular Outcomes in Elderly Patients: A Post Hoc Analysis of a Randomized Controlled Trial

2018 ◽  
Vol 170 (6) ◽  
pp. 423 ◽  
Author(s):  
Matthew P. Gilbert ◽  
Stephen C. Bain ◽  
Edward Franek ◽  
Esteban Jodar-Gimeno ◽  
Michael A. Nauck ◽  
...  
Keyword(s):  
Randomized Controlled Trial ◽  
Elderly Patients ◽  
Controlled Trial ◽  
Cardiovascular Outcomes ◽  
Post Hoc Analysis ◽  
Randomized Controlled ◽  
Post Hoc

scholarly journals Marked Reduction in 28-Day Mortality among Elderly Patients with Severe Community-Acquired Pneumonia: Post Hoc Analysis of XueBiJing Injection Randomized Controlled Trial

2020 ◽  
Author(s):  
Yan Liu ◽  
Chi Zhang ◽  
Chengyu Li ◽  
Chunxue Bai ◽  
Hongcai Shang
Keyword(s):  
Elderly Patients ◽  
Controlled Trial ◽  
Total Duration ◽  
Community Acquired Pneumonia ◽  
Post Hoc Analysis ◽  
Improved Outcomes ◽  
Severe Community Acquired Pneumonia ◽  
Favorable Safety ◽  
Post Hoc ◽  
Case Mortality

Abstract Background There were a few studies on the case mortality of severe community-acquired pneumonia (CAP) in elderly people. Improved outcomes with XueBiJing (XBJ) Injection versus placebo have been shown in overall trial populations. We investigated the efficacy and safety of XBJ versus placebo in subjects with severe CAP stratified by age (<65 and ≥ 65 years). Methods This post hoc analysis of a large randomized trial compared data from elder and nonelderly patients with XBJ, 100 ml, q12h, or a visually indistinguishable placebo for 5-7 days. Results Among subjects ≥65 years (n=291), 23 (16.0%) XBJ recipients and 41 (27.9%) placebo recipients ( P =0.014) died within 28 days. Among subjects <65 years (n=360), XBJ still had lower mortality (XBJ 15.6% verse placebo 22.8%; P =0.082), without significantly statistical difference. Total duration of ICU stay and the time of mechanical ventilation were similar in both groups ( P > 0.05). XBJ also had a favorable safety profile, with no clinically relevant differences between two groups. The overall incidence of adverse events was similar in both groups. Conclusions XBJ was safe and effective for reduction in 28-day mortality among elderly patients with severe CAP. Additional trials involving elderly patients are needed to further confirm the present results.

Sign in / Sign up

Export Citation Format

Share Document